Europe
Genfit, with offices in Lille, France and Cambridge, Mass., launched its initial public offering (IPO) on the Nasdaq on March 27. Dean Hum, chief operating officer of Genfit, took time out to speak with BioSpace about the company, the IPO and elafibranor.
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
Novartis will quickly roll Mayzent out to U.S. physicians. The Swiss pharma giant plans to make the drug available within one week of the FDA approval.
LNC Therapeutics intends to develop a new class of drugs based on christensenella for the treatment of obesity, metabolic diseases, and other serious indications with significant unmet medical needs
Evotec and the mark foundation form first collaboration together to advance oncology assets based on evotec’s new allosteric inhibitor platform “Targetallomod”
The world-renowned HGH Infrared Systems is developing its brand image and communication strategy to better reflect its position as a global leader in the optronics market.
ELATUR® DPT enables fast and simple production of flexible PVC products such as floor and wall coverings
The shareholders of Immunicum AB, reg. no 556629-1786, are hereby invited to the Annual General Meeting on Thursday, 25 April 2019, at 10:30, at Sturegatan 15’s premises, at Sturegatan 15, SE-161 14 36 Stockholm.
The prevalence of using antidepressants and proton pump inhibitors increases after the diagnosis of Alzheimer’s disease, according to a doctoral dissertation from the University of Eastern Finland.
PRESS RELEASES